Antibody enhanced HPLC for serotype-specific quantitation of polysaccharides in pneumococcal conjugate vaccine

JZ Deng, N Kuster, A Drumheller, M Lin, F Ansbro… - npj Vaccines, 2023 - nature.com
Bacterial infection remains as one of the major healthcare issues, despite significant
scientific and medical progress in this field. Infection by Streptococcus Pneumoniae (S …

Identification and Quantification of a Pneumococcal Cell Wall Polysaccharide by Antibody-Enhanced Chromatography Assay

JZ Deng, Z Chen, J Small, Y Yuan, K Cox, A Tang… - Vaccines, 2024 - mdpi.com
Multivalent pneumococcal vaccines have been developed successfully to combat invasive
pneumococcal diseases (IPD) and reduce the associated healthcare burden. These …

Current trends in development and manufacturing of higher-valent pneumococcal polysaccharide conjugate vaccine and its challenges

SS Jain, VK Singh, RK Kante, SK Jana, RH Patil - Biologicals, 2024 - Elsevier
Pneumococcal conjugate vaccines (PCVs) have been developed to protect against
pneumococcal diseases caused by the more than 100 serotypes of the bacterium …

Next generation pneumococcal vaccines

KL Moffitt, R Malley - Current opinion in immunology, 2011 - Elsevier
Currently licensed pneumococcal vaccines are based on the generation of antibodies to the
pneumococcal polysaccharide, of which there are more than 90 different types. While these …

Immunogenicity and protective efficacy of a prototype pneumococcal bioconjugate vaccine

J Aceil, AV Paschall, CJ Knoot, LS Robinson, NE Scott… - Vaccine, 2022 - Elsevier
Capsular polysaccharides (CPSs), with which most pathogenic bacterial surfaces are
decorated, have been used as the main components of glycoconjugate vaccines against …

Evaluation and optimization of an ELISA procedure to quantify antibodies against pneumococcal polysaccharides included in the 13-valent conjugate vaccine

S Belmonti, F Lombardi, M Morandi… - … of Immunoassay and …, 2016 - Taylor & Francis
The 13-valent pneumococcal conjugate vaccine (PCV-13) is recommended for HIV-infected
people, although its effectiveness in this population remains under evaluation. In this study …

Serotype-specific quantification of residual free polysaccharide in multivalent pneumococcal conjugate vaccines

M Grozdanovic, R Samuel, B Grau, F Ansbro - Glycoconjugate Journal, 2024 - Springer
The Streptococcus pneumoniae bacteria has over 100 known serotypes that display a
continuous change in prevalence by patients' age and geographical location and therefore …

Development of 5-valent conjugate pneumococcal protein A–Capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease

C Meng, H Lin, J Huang, H Wang, Q Cai, L Fang… - Microbial …, 2009 - Elsevier
In this study, we synthesized a 5-valent pneumococcal conjugate vaccine, which was
prepared with the pneumococcal capsular polysaccharides (PCPs)(from Streptococcus …

Characterization of high molecular weight pneumococcal conjugate by SEC-MALS and AF4-MALS

JZ Deng, J Lin, M Chen, C Lancaster, P Zhuang - Polymers, 2022 - mdpi.com
Infections by Streptococcus pneumoniae can cause serious pneumococcal diseases and
other medical complications among patients. Polysaccharide-based vaccines have been …

Quantitation and characterization of serotype 6A activation for pneumococcal conjugate vaccine by cryo-EM and SEC methods

M Lin, JZ Deng, G Scapin, Y Yuan, Y Gomez-Llorente… - Vaccine, 2024 - Elsevier
Pneumococcal conjugate vaccines (PCV) typically consist of capsular polysaccharides from
different S. pneumoniae serotypes which are covalently attached to carrier protein. A well …